Resorbable Embolisation Technology

Built from organic biocompatible materials

Restores blood flow to the targeted area

Minimises the impact of non-target embolisation

Resorbable Microspheres for Improved Patient Outcomes

Permanent microspheres have existed for more than 20 years, and are routinely used to treat liver cancer, uterine fibroids and benign prostate hyperplasia. Resorbable microspheres can be used to treat a range of new indications where it is desirable to restore blood flow to the targeted area after the desired therapeutic effect has been achieved.

This restoration of flow can be necessary to ensure a sufficient long term blood supply to downstream tissue, to minimise the effect of non-target embolisation or to facilitate repeat procedures. 

These resorbable microspheres have new applications in Knee Osteoarthritis (KOA), Adhesive Capsulitis (frozen shoulder), treatment of pain pre- and post-knee replacement, various tendinopathies including plantar fasciitis, pancreatic cancer, along with the potential to replace permanent beads in existing applications. 

Learn More About Clinical Applications

Patented Process to Leave No Trace

There is a strong and growing patient preference not to leave anything behind in the body.

CrannMed’s resorbable technology is built from organic biocompatible materials. Microsphere degradation within the vasculature is controlled using an embedded enzyme that exclusively targets the base material of the microsphere. Our pre-clinical trials have given us confidence our technology leaves no trace behind. Our microspheres have no other targets within the human body which ensures a controlled degradation of the microspheres completely independent to the physiological response of the patient.

The duration of reabsorption can be customised from a few hours to six months. The manufacturing technology ensures market leading size distribution, long term iso-buoyancy and excellent deliverability; demonstrating fill efficiency in challenge testing. This time-lapse of angiographic images convey  the impact of embolisation with EmboSure over period of resorption. Complete revascularisation occurs by T5. This tunable technology has the potential to deliver therapeutic agents which opens many additional applications.

Both the technology and the manufacturing process are protected by a suite of international patent applications.